JAGA Study: Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

Individuals with a confirmed diagnosis of Aicardi-Goutières syndrome (AGS) may be eligible for a compassionate use study of baricitinib, a JAK 1/2-inhibitor.

Compassionate use studies, also known as expanded access programs, allow pharmaceutical companies to provide their experimental drugs to individuals outside of formal clinical trials who may benefit from their use.  

Given that AGS is an interferon-mediated disease, patients diagnosed with this disorder are expected to benefit from JAK1 and JAK2 inhibition and, thus, from treatment with baricitinib.

If your child has a confirmed diagnosis of Aicardi-Goutières syndrome, please submit our Referral Survey and the JAGA study coordinator will contact you with more information.